Amgen snags genetics outfit for $415M; Knee replacement may spur weight gain;

 @FierceMedDev: A Finnish company won CE mark status for noninvasive magnetic stimulation to treat major depression. News | Follow @FierceMedDev

@MarkHFierce: GE has clearly wanted Insightec for a long time. The Israeli company uses MRI-guided ultrasound to ablate tissue. Release | Follow @MarkHFierce

 @DamianFierce: Covance says it's the first global CRO to get GLP certification from Chinese regulators. More | Follow @DamianFierce

> German orthopedics device company aap Implantate gained 510(k) clearance for the company's signature anatomic orthopedic trauma plating system. Release

> Amgen ($AMGN) just snatched up deCODE Genetics--an Icelandic gene sequencer of some renown that was forced into bankruptcy back in 2009--for $415 million. Story

> Some see the movement to repeal the 2.3% medical device tax as gaining momentum, perhaps even as part of the year-end negotiations to avoid the so-called fiscal cliff. Blog

> Knee-replacement surgery may increase a person's chances of gaining weight, according to a new study. Story

> Researchers are working with advanced computer programs--much like IBM's Watson--designed to make diagnostics faster and more reliable. News

> The legal battle over transvaginal mesh continues, as more women have joined a class-action suit against Boston Scientific ($BSX). More

> Leica Biosystems will work with Galena Biopharma to develop a companion diagnostic for Galena's NeuVax breast cancer therapeutic. Item

Biotech News

 @FierceBiotech: Piramal continues market-access blitz with Abacus takeover. Story | Follow @FierceBiotech

@JohnCFierce: Isis gets $30M up front in a new pact with Biogen to develop antisense drugs. $200M per in biobucks. News | Follow @JohnCFierce

 @RyanMFierce: Wow. Amgen buying deCODE for $415M. Wants to validate disease targets for drug development. | Follow @RyanMFierce

> Biogen embraces Isis again in early-stage collaboration worth up to $630M. Story

> ASH roundup: Pharmacyclics' ibrutinib seizes center stage with more promising leukemia results. Report

> Takeda's oral successor to Velcade benefits blood cancer patients. News

Pharma News

@FiercePharma: Pay-for-delay to get Supreme Court consideration. News | Follow @FiercePharma

> Bloomberg: SEC looking at InterMune trades by hedge fund. Story

> Eliquis from Pfizer, Bristol-Myers Squibb shows potential for longer use. Report

> FDA panel says no to high-powered painkiller. Article

Biotech IT News

> Consortium sifting through MS data to find new endpoint. Report

> Piramal continues market-access blitz with Abacus takeover. News

> Internet advocate slams pharma's social media moves. Story

> Survey: Pharma's social media, mobile use spreads in 2012. Article

CRO News

> Recipharm bets on analytical development with expansion. More

> Covance notches GLP nod from Chinese regulators. Report

> Alimera taps Quintiles to commercialize Iluvien. News

> AMRI re-ups with GE Healthcare, its largest supply partner. Story

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.